Sign in
Taking peoplePhase 2

Etanercept compared with methotrexate for giant cell arteritis

Compares etanercept and methotrexate for lasting remission without steroids in giant cell arteritis.

Key facts

Who runs it
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
Where
Poland6 sites in 1 countryChoose a country to see its sites
Registry title
A randomized trial comparing efficacy and safety of etanercept and methotrexate in giant cell arteritis (EFFECTA)
Status
Recruiting
Phase
Phase 2
People taking part
88 people, planned
Started
12 Mar 2025
Expected to end
30 Nov 2028
Type of study
Interventional
Record updated
24 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 50 or older with active giant cell arteritis (GCA). It compares etanercept with methotrexate for keeping the disease quiet without steroids.

Age
50 years and older (the record lists 18 years as the minimum, but the criteria require age ≥ 50 years).
Sex
All sexes can join.
Disease stage
Active GCA that is new, refractory (not responding to treatment) or relapsing. Symptoms must come from the disease, with ESR ≥ 30 mm/1 hour or CRP ≥ 10 mg/L at screening or within 8 weeks before.
Earlier treatment
No oral steroids above 60 mg/day prednisone and no steroids by injection or drip within 2 weeks. No methotrexate, TNFα inhibitors or similar drugs within 12 weeks. No cyclophosphamide, immunoglobulins or plasmapheresis within 6 months. No anti-CD20 antibodies within 12 months. No long-term steroids for other reasons.
Biomarker or test result
Raised inflammation markers: ESR ≥ 30 mm/1 hour or CRP ≥ 10 mg/L.

Main reasons for not taking part

  • Reduced blood flow to vital organs caused by GCA, or serious heart disease, stroke or heart attack within 6 months
  • Cancer within 5 years, with a few skin and cervical exceptions
  • Hepatitis B, hepatitis C, HIV or tuberculosis test positive, or severe liver or kidney problems
  • Pregnancy, breastfeeding or planning either during the study
  • Past major organ transplant, demyelinating disease or other autoimmune rheumatic disease

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Patient’s written informed consent to participate in the study
  • Age ≥ 50 years
  • Diagnosis of GCA according to 2022 American College of Rheumatology/EULAR classification criteria for GCA or, in the case of involvement of only extracranial arteries, patients with a diagnosis of GCA based on medium or large-sized arterities that occurred at the age of ≥ 50 years and was confirmed by imaging, i.e. ultrasound, CT, MRI, conventional angiography or PET-CT, at the time of screening or in the past
  • New onset, refractory or relapsing GCA
  • Active GCA, defined as the presence of symptoms or signs attributed to GCA and not related to prior damage and elevated inflammatory markers, i.e. ESR ≥ 30 mm/1 hour or CRP ≥ 10 mg/L attributed to active GCA at screening or within 8 weeks prior to screening
  • Women of child-bearing potential and men who are sexually active with a woman of child-bearing potential must agree to the use of contraception with an adequate level of effectiveness during treatment with methotrexate/etanercept and for at least 6 months after its completion

Who cannot take part

  • Moderate or severe heart failure (New York Heart Association class III or IV), unstable ischemic heart disease, a stroke or myocardial infarction within 6 months prior to screening, or other cardiovascular disease that, in the Investigator’s opinion, would expose the patient to an unacceptable risk in case of participation in the study
  • A malignancy within 5 years prior to screening, except for: a. A completely resected cervical carcinoma in situ with no signs of recurrence within 12 months prior to screening; b. A completely cured basal cell skin carcinoma with no signs of recurrence within 12 months prior to screening
  • Previous use of the following treatment: a. Within 2 weeks prior to randomization: oral corticosteroids (CS) >60 mg/day prednisone or equivalent, parenteral CS; b. Within 12 weeks prior to randomization: methotrexate, leflunomide, sulfasalazine, chloroquine, hydroxychloroquine, azathioprine, cyclosporine A, mycophenolate mofetil, TNFα inhibitors, anakinra, abatacept, IL-17 blockers; c. Within 6 months prior to randomization: immunoglobulins, plasmapheresis, cyclophosphamide or other alkylating agents; d. Within 12 months prior to randomization: anti-CD20 antibodies; e. Oral or parenteral CS used chronically for reasons other than GCA
  • Abuse or addiction to drugs, alcohol or psychoactive substances
  • Live/attenuated vaccinations within 3 months prior to screening or planned administration of live vaccination during the study period
  • Use of other investigational drugs within 12 weeks or 5 half-lives, whichever is longer, prior to screening
  • Major surgery within 3 months prior to screening or major surgery planned during the study period
  • Presence of ischemia of organ important for the patient’s survival (e.g. central nervous system, heart, lungs, kidneys, alimentary tract) in the course of GCA
  • Severe renal impairment
  • Other severe disease (including, but not limited to, respiratory, nervous, endocrine, digestive, urinary tract disease) for which, in the Investigator’s opinion, participating in the study would expose patient to an unacceptable risk
  • Presence or history of other chronic autoimmune rheumatic disease that could interfere with the evaluation of the results of the following study, including: systemic lupus erythematosus, rheumatoid arthritis, or other systemic connective tissue disease, other than GCA systemic vasculitis
  • Active stomach or duodenal ulcer
  • Presence or history of demyelinating syndrome
  • History of major organ transplant (kidneys, lungs, heart, liver)
  • Hypersensitivity to methotrexate, etanercept or any other excipients of the methotrexate or etanercept
  • Acute, recurrent or chronic infection (e.g. tuberculosis, HIV infection) for which, in the Investigator’s opinion, participating in the study would expose patient to an unacceptable risk
  • The following abnormalities in laboratory tests at screening: a. WBC < 3 G/L; b. NEU < 1 G/L; c. HGB < 9 g/dL; d. PLT < 100 G/L; e. ALT > 2 x ULN; f. AST > 2 x ULN; g. Total bilirubin >1,5 x ULN; h. eGFR < 50ml/min/1,73 m2; i. positive HBsAg; j. positive anti-HBc (total); k. positive anti-HCV; l. positive anti-HIV; m. positive or equivocal Quantiferon-TB Gold test
  • Severe liver dysfunction
  • Bone marrow hypoplasia
  • Positive result of a pregnancy test performed in women of child-bearing potential at screening or Visit 1
  • Pregnancy or planned pregnancy during the study
  • Breastfeeding or planned breastfeeding during the study
  • Lack of patient cooperation
  • Oral mucous ulcers

This trial is currently available in Poland.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To compare the effectiveness of treatment with etanercept (ETN) versus methotrexate (MTX) in the induction of sustained steroid-free remission in patients with giant cell arteritis (GCA).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A randomized trial comparing efficacy and safety of etanercept and methotrexate in giant cell arteritis (EFFECTA)
Plain-language title
Etanercept compared with methotrexate for giant cell arteritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
24 February 2026